144 related articles for article (PubMed ID: 31648015)
1. Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy.
Lee SH; Heng D; Teo JWP; Toh FKY; Tan RBH
Int J Pharm; 2019 Dec; 572():118740. PubMed ID: 31648015
[TBL] [Abstract][Full Text] [Related]
2. A novel inhaled multi-pronged attack against respiratory bacteria.
Lee SH; Teo J; Heng D; Zhao Y; Ng WK; Chan HK; Tan LT; Tan RB
Eur J Pharm Sci; 2015 Apr; 70():37-44. PubMed ID: 25612805
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
[TBL] [Abstract][Full Text] [Related]
4. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy.
Shur J; Nevell TG; Ewen RJ; Price R; Smith A; Barbu E; Conway JH; Carroll MP; Shute JK; Smith JR
J Pharm Sci; 2008 Nov; 97(11):4857-68. PubMed ID: 18351636
[TBL] [Abstract][Full Text] [Related]
5. Conception, preparation and properties of functional carrier particles for pulmonary drug delivery.
Odziomek M; Sosnowski TR; Gradoń L
Int J Pharm; 2012 Aug; 433(1-2):51-9. PubMed ID: 22580211
[TBL] [Abstract][Full Text] [Related]
6. Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy.
Lee SH; Teo J; Heng D; Ng WK; Zhao Y; Tan RB
J Pharm Sci; 2016 Apr; 105(4):1501-12. PubMed ID: 27019964
[TBL] [Abstract][Full Text] [Related]
7. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
8. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
Manniello MD; Del Gaudio P; Aquino RP; Russo P
Int J Pharm; 2017 Nov; 533(2):463-469. PubMed ID: 28377314
[TBL] [Abstract][Full Text] [Related]
9. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
10. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
11. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
12. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
[TBL] [Abstract][Full Text] [Related]
13. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
15. Sodium hyaluronate dry powder inhalation in combination with sodium cromoglycate prepared using optimized spray drying conditions.
Yildiz Türkyilmaz G; Özdokur KV; Alparslan L; Karasulu E
Pharm Dev Technol; 2023 Feb; 28(2):240-247. PubMed ID: 36730066
[TBL] [Abstract][Full Text] [Related]
16. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections.
Matinkhoo S; Lynch KH; Dennis JJ; Finlay WH; Vehring R
J Pharm Sci; 2011 Dec; 100(12):5197-205. PubMed ID: 22020816
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Ciprofloxacin Hydrochloride Spray-Dried Microparticles for Pulmonary Delivery Using Design of Experiments.
Razuc M; Piña J; Ramírez-Rigo MV
AAPS PharmSciTech; 2018 Oct; 19(7):3085-3096. PubMed ID: 30105497
[TBL] [Abstract][Full Text] [Related]
18. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
Weers JG; Miller DP; Tarara TE
AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
[TBL] [Abstract][Full Text] [Related]
19. Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.
Sommerfeld Ross S; Gharse S; Sanchez L; Fiegel J
Int J Pharm; 2017 Oct; 531(1):14-23. PubMed ID: 28826725
[TBL] [Abstract][Full Text] [Related]
20. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
